Chloroquine as a potential adjunctive therapy in tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Confirmation of preclinical data on tioureidoiminomethylpyridinium perchlorate in treatment of MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Immuno-allergic reactions to antituberculosis treatment Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013
Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Side effects of tuberculosis treatment with fixed-dose combinations Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Identifying genetic susceptibility to isoniazid- induced hepatitis Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013
Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Anticancer chemotherapy combined with anti-tuberculosis treatment: A systematic review Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Impact of food intake on pharmacokinetics(PK) of first-line tuberculosis drugs in treatment-naive patients Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Pharmacokinetic characteristics of ethambutol hydrochloride depending on the way of administration Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
Advantages of intravenous chemotherapy for tuberculosis patients with viral hepatitis Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Association of serum cytokines with pulmonary tuberculosis treatment outcomes Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
Risk factors for anti-TB drug resistance in Poland Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Drug resistance among new TB cases in some Russian regions Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016